American Century Companies Inc. raised its stake in shares of Heska Corp (NASDAQ:HSKA) by 10.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 48,577 shares of the medical research company’s stock after purchasing an additional 4,401 shares during the quarter. American Century Companies Inc. owned 0.65% of Heska worth $5,042,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Curbstone Financial Management Corp boosted its holdings in Heska by 11.8% during the second quarter. Curbstone Financial Management Corp now owns 5,700 shares of the medical research company’s stock valued at $592,000 after purchasing an additional 600 shares in the last quarter. Rhumbline Advisers boosted its holdings in Heska by 4.2% during the first quarter. Rhumbline Advisers now owns 15,399 shares of the medical research company’s stock valued at $1,218,000 after purchasing an additional 614 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its holdings in Heska by 23.0% during the second quarter. State Board of Administration of Florida Retirement System now owns 3,581 shares of the medical research company’s stock valued at $372,000 after purchasing an additional 670 shares in the last quarter. Swiss National Bank boosted its holdings in Heska by 6.6% during the first quarter. Swiss National Bank now owns 11,300 shares of the medical research company’s stock valued at $893,000 after purchasing an additional 700 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. boosted its holdings in Heska by 19.6% during the first quarter. Oppenheimer Asset Management Inc. now owns 5,270 shares of the medical research company’s stock valued at $416,000 after purchasing an additional 863 shares in the last quarter. 89.17% of the stock is currently owned by institutional investors.
Shares of HSKA opened at $102.61 on Friday. The company has a market capitalization of $802.26 million, a PE ratio of 49.57 and a beta of 0.52. Heska Corp has a one year low of $56.59 and a one year high of $111.34.
Heska (NASDAQ:HSKA) last announced its earnings results on Tuesday, August 7th. The medical research company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.17 by $0.07. The business had revenue of $29.66 million for the quarter, compared to the consensus estimate of $30.19 million. Heska had a return on equity of 11.49% and a net margin of 4.67%. research analysts anticipate that Heska Corp will post 1.67 earnings per share for the current fiscal year.
In related news, EVP Steven M. Eyl sold 1,051 shares of the business’s stock in a transaction that occurred on Friday, August 10th. The shares were sold at an average price of $98.00, for a total value of $102,998.00. Following the completion of the transaction, the executive vice president now owns 15,401 shares in the company, valued at approximately $1,509,298. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Jason A. Napolitano sold 1,200 shares of the business’s stock in a transaction that occurred on Monday, July 9th. The stock was sold at an average price of $110.00, for a total transaction of $132,000.00. The disclosure for this sale can be found here. Insiders sold a total of 52,778 shares of company stock worth $5,282,310 over the last three months. 14.70% of the stock is owned by company insiders.
A number of equities research analysts have weighed in on HSKA shares. ValuEngine raised Heska from a “hold” rating to a “buy” rating in a report on Monday, July 2nd. BidaskClub raised Heska from a “buy” rating to a “strong-buy” rating in a report on Friday, July 6th. Canaccord Genuity reissued a “buy” rating and issued a $115.00 target price (up from $100.00) on shares of Heska in a report on Friday, May 18th. Benchmark boosted their target price on Heska from $120.00 to $143.00 and gave the stock a “buy” rating in a report on Monday, May 21st. They noted that the move was a valuation call. Finally, Zacks Investment Research downgraded Heska from a “hold” rating to a “sell” rating in a report on Thursday, August 9th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. Heska has an average rating of “Hold” and an average price target of $107.50.
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.
Recommended Story: Hedge Funds
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.